Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR

Oncogene volume 27, pages 585–595 (2008)Cite this article

Abstract

The mammalian target of rapamycin (mTOR) is a large, multidomain protein kinase, which plays a central role in the regulation of cell growth and has recently emerged as an essential target of survival signals in many types of human cancer cells. Here, we report the solution structures of complexes formed between the FKBP12-rapamycin binding (FRB) domain of mTOR and phosphatidic acid, an important cellular activator of the kinase, and between the FRB domain and a novel inhibitor (HTS-1). The overall structure of the FRB domain is very similar to that seen in the ternary complex formed with FKBP12 and the immunosuppressive drug rapamycin; however, there are significant changes within the rapamycin-binding site with important consequences for rational drug design. The surface of the FRB domain contains a number of distinctive features that have previously escaped attention, including a potential new regulatory site on the opposite face to that involved in the binding of rapamycin, which displays the features expected for a specific binding site for a small molecule. The interaction sites for phosphatidic acid and HTS-1 were found to closely match the site responsible for rapamycin binding. In addition, the structures determined for the FRB–phosphatidic acid and FRB–HTS-1 complexes revealed a striking similarity between the conformations of buried portions of the ligands and that seen for the rapamycin backbone in contact with the domain. Our findings further highlight the importance of the FRB domain in small molecule-mediated regulation of mTOR, demonstrate the ability to identify novel inhibitors of mTOR that bind tightly to the rapamycin-binding site in the absence of FKBP12, and identify a potential new regulatory site that may be exploited in the design of new anticancer drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Annis DA, Athanasopoulos J, Curran PJ, Felsch JS, Kalghatgi K, Lee WH et al. (2004). An affinity selection-mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries—discovery of a novel antagonist of E-coli dihydrofolate reductase. Int J Mass Spectrom 238: 77–83.

    CAS  Google Scholar 

  • Avila-Flores A, Santos T, Rincon E, Merida I . (2005). Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J Biol Chem 280: 10091–10099.

    Article  CAS  PubMed  Google Scholar 

  • Banaszynski LA, Liu CW, Wandless TJ . (2005). Characterization of the FKBP center dot rapamycin center dot FRB ternary complex. J Am Chem Soc 127: 4715–4721.

    Article  CAS  PubMed  Google Scholar 

  • Bianco RB, Melisi D, Ciardiello F, Tortora G . (2006). Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42: 290–294.

    Article  CAS  PubMed  Google Scholar 

  • Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS et al. (1994). A mammalian protein targeted by G1-arresting rapamycin–receptor complex. Nature 369: 756–758.

    Article  CAS  PubMed  Google Scholar 

  • Chen J, Fang Y . (2002). A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64: 1071.

    Article  CAS  PubMed  Google Scholar 

  • Chen YH, Zheng Y, Foster DA . (2003). Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22: 3937–3942.

    Article  CAS  PubMed  Google Scholar 

  • Choi JW, Chen J, Schreiber SL, Clardy J . (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273: 239–242.

    Article  CAS  Google Scholar 

  • DeLano WL . (2002). The PyMOL molecular graphics system. http://www.pymol.org.

  • Dominguez C, Boelens R, Bonvin AM . (2003). HADDOCK: a protein–protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125: 1731–1737.

    Article  CAS  PubMed  Google Scholar 

  • Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J . (2001). Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942–1945.

    Article  CAS  PubMed  Google Scholar 

  • Farmer BT, Constantine KL, Goldfarb V, Friedrichs MS, Wittekind M, Yanchunas J et al. (1996). Localizing the NADP+ binding site on the MurB enzyme by NMR. Nat Struct Mol Biol 3: 995.

    Article  CAS  Google Scholar 

  • Foster DA . (2007). Regulation of mTOR by phosphatidic acid? Cancer Res 67: 1–4.

    Article  CAS  PubMed  Google Scholar 

  • Guertin DA, Sabatini DM . (2005). An expanding role for mTOR in cancer. Trends Mol Med 11: 353–361.

    Article  CAS  PubMed  Google Scholar 

  • Guntert P, Wuthrich K . (1991). Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints. J Biomol NMR 1: 447–456.

    Article  CAS  PubMed  Google Scholar 

  • Hancock JF . (2007). PA promoted to manager. Nat Cell Biol 9: 615–617.

    Article  CAS  PubMed  Google Scholar 

  • Hara K, Maruki Y, Long XM, Yoshino K, Oshiro N, Hidayat S et al. (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177–189.

    Article  CAS  PubMed  Google Scholar 

  • Hay N, Sonenberg N . (2004). Upstream and downstream of mTOR. Gene Dev 18: 1926–1945.

    Article  CAS  PubMed  Google Scholar 

  • Heitman J, Movva NR, Hall MN . (1991). Targets for cell-cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905–909.

    Article  CAS  PubMed  Google Scholar 

  • Herrmann T, Guntert P, Wuthrich K . (2002). Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. J Mol Biol 319: 209–227.

    Article  CAS  PubMed  Google Scholar 

  • Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biol 6: 1122–1128.

    Article  CAS  PubMed  Google Scholar 

  • Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. (2002). MTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163–175.

    Article  CAS  PubMed  Google Scholar 

  • Kleywegt GJ, Jones TA . (1997). Model building and refinement practice. Method Enzymol 277: 208–230.

    Article  CAS  Google Scholar 

  • Koharudin LM, Bonvin AM, Kaptein R, Boelens R . (2003). Use of very long-distance NOEs in a fully deuterated protein: an approach for rapid protein fold determination. J Magn Reson 163: 228–235.

    Article  CAS  PubMed  Google Scholar 

  • Koradi R, Billeter M, Wuthrich K . (1996). MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14: 51–55.

    Article  CAS  PubMed  Google Scholar 

  • Kunz J, Henriquez R, Schneider U, Deuterreinhard M, Movva NR, Hall MN . (1993). Target of rapamycin in yeast, Tor2, is an essential phosphatidylinositol kinase homolog required for G(1) progression. Cell 73: 585–596.

    Article  CAS  PubMed  Google Scholar 

  • Laskowski RA, Rullmann JAC, MacArthur MW, Kaptein R, Thornton JM . (1996). AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8: 477–486.

    Article  CAS  PubMed  Google Scholar 

  • Leone M, Crowell KJ, Chen JH, Jung DW, Chiang GG, Sareth S et al. (2006). The FRB domain of mTOR: NMR solution structure and inhibitor design. Biochemistry 45: 10294–10302.

    Article  CAS  PubMed  Google Scholar 

  • Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D et al. (2002). Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457–468.

    Article  CAS  PubMed  Google Scholar 

  • Long XM, Ortiz-Vega S, Lin YS, Avruch J . (2005). Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280: 23433–23436.

    Article  CAS  PubMed  Google Scholar 

  • Manning BD . (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167: 399–403.

    Article  CAS  PubMed  Google Scholar 

  • Mor A, Campi G, Du G, Zheng Y, Foster DA, Dustin ML et al. (2007). The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2. Nat Cell Biol 9: 713–719.

    Article  CAS  PubMed  Google Scholar 

  • Muskett FW, Frenkiel TA, Feeney J, Freedman RB, Carr MD, Williamson RA . (1998). High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3. J Biol Chem 273: 21736–21743.

    Article  CAS  PubMed  Google Scholar 

  • Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N . (2006). mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195–199.

    Article  CAS  PubMed  Google Scholar 

  • Sabatini DM, Erdjumentbromage H, Lui M, Tempst P, Snyder SH . (1994). Raft1—a mammalian protein that binds to Fkbp12 in a rapamycin-dependent fashion and is homologous to yeast tors. Cell 78: 35–43.

    Article  CAS  PubMed  Google Scholar 

  • Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296–1302.

    Article  CAS  PubMed  Google Scholar 

  • Sarbassov DD, Ali SM, Sabatini DM . (2005). Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596–603.

    Article  CAS  PubMed  Google Scholar 

  • Thomas GV . (2006). mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 16: 78–84.

    Article  CAS  PubMed  Google Scholar 

  • Veverka V, Lennie G, Crabbe T, Bird I, Taylor RJ, Carr MD . (2006). NMR assignment of the mTOR domain responsible for rapamycin binding. J Biomol NMR 36 (Suppl, 5): 3.

    Article  PubMed  Google Scholar 

  • Vezina C, Kudelski A, Sehgal SN . (1975). Rapamycin (Ay-22,989), a new antifungal antibiotic. 1. Taxonomy of producing streptomycete and isolation of active principle. J Antibiot 28: 721–726.

    Article  CAS  PubMed  Google Scholar 

  • Williamson RA, Carr MD, Frenkiel TA, Feeney J, Freedman RB . (1997). Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation. Biochemistry 36: 13882–13889.

    Article  CAS  PubMed  Google Scholar 

  • Wullschleger S, Loewith R, Hall MN . (2006). TOR signaling in growth and metabolism. Cell 124: 471–484.

    Article  CAS  Google Scholar 

  • Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D . (2007). Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 9: 707–712.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by UCB-Celltech Ltd and the Wellcome Trust. HTS-1 was identified through a high-throughput screen carried out by NeoGenesis Pharmaceuticals Inc., using their Automated Ligand Identification System (ALIS) and we thank Dr Huw Nash for his assistance.

Author information

Authors and Affiliations

  1. Department of Biochemistry, University of Leicester, Leicester, UK

    V Veverka, F W Muskett & M D Carr

  2. UCB R&D, Slough, UK

    T Crabbe, I Bird, G Lennie & R J Taylor

Authors
  1. V Veverka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Crabbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Bird
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Lennie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F W Muskett
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R J Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M D Carr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M D Carr.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Veverka, V., Crabbe, T., Bird, I. et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 27, 585–595 (2008). https://doi.org/10.1038/sj.onc.1210693

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210693

Keywords

Search

Advanced search

Quick links